Advancing Biological Evaluation for Medical Devices: MDLExpands Comprehensive Testing Capabilities

Medical device companies often face challenges during biological evaluation and regulatory review, including incomplete test coverage, insufficient data depth, and gaps in immunotoxicity or blood compatibility assessments.

MDL has recently enhanced its biological evaluation service platform to address these challenges, providing more comprehensive and regulatory-aligned testing solutions for global clients.

Addressing Common Gaps in Biological Evaluation

In practice, many projects encounter issues such as:

• Incomplete mucosal irritation testing coverage
• Limited blood compatibility evaluation (e.g., hemolysis only)
• Insufficient genotoxicity data packages
• Lack of robust immunotoxicity assessment

MDL’s upgraded capabilities are designed to systematically resolve these gaps and support more robust regulatory submissions.

Comprehensive Testing Capabilities

Full-Scope Mucosal Irritation Testing

Coverage across five key mucosal types:

• Ocular
• Vaginal
• Penile
• Rectal
• Oral

Advanced Blood Compatibility Evaluation

Beyond standard hemolysis testing, MDL provides integrated assessments including:

• Platelet activation
• Complement activation
• Coagulation pathways
• Thrombosis-related endpoints

With biomarker-level analysis such as:

• β-TG
• PF4
• TxB2

Full Genotoxicity Testing Panel

Aligned with GB/T 16886.3-2019, including:

• Ames test
• Micronucleus test
• Chromosomal aberration test
• Mouse lymphoma TK assay

Expanded Immunotoxicity Assessment

Based on GB/T 16886.20-2015, including:

• T lymphocyte transformation test
• Flow cytometry for lymphocyte subsets
• α-Gal antigen clearance (for animal-derived devices)
• Plaque-forming cell assay

From Basic Testing to Integrated Evaluation

Compared with conventional testing approaches, MDL provides:

• Multi-endpoint blood compatibility analysis instead of single hemolysis tests
• Advanced immunogenicity profiling beyond basic IgG/IgM detection
• Integrated evaluation strategies aligned with regulatory expectations

Global Recognition and Compliance

MDL holds both CMA and CNAS accreditations, with recognition under ILAC-MRA, ensuring:

• International acceptance of testing data
• Alignment with global regulatory requirements
• Enhanced credibility in submission dossiers

Toprion’s Role

As MDL’s international partner, Toprion provides overseas clients with direct access to CNASaccredited laboratory services. We ensure efficient communication, project coordination, and reliable delivery for global collaborations.

Looking Ahead

This accreditation reflects MDL’s ongoing commitment to delivering high-quality, compliant preclinical services aligned with global standards.